公开(公告)号：US20180161307A1

公开(公告)日：2018-06-14

申请号：US15686499

申请日：2017-08-25

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC: A61K31/403 ,  A61K31/16 ,  A61K31/03 ,  A61K31/38 ,  A61K31/4192 ,  A61P31/20

CPC classification number: A61K31/403 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192 ,  A61P31/20 ,  C07D487/04 ,  C07D519/00

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US20180065953A1

公开(公告)日：2018-03-08

申请号：US15680045

申请日：2017-08-17

Applicant: Gilead Sciences, Inc.

Inventor： Jerry Evarts ,  Joshua A. Kaplan ,  Musong Kim ,  Devan Naduthambi ,  Leena Patel ,  Stephane Perreault ,  Gary Phillips ,  Lafe J. Purvis, II ,  Kirk L. Stevens ,  Jennifer Anne Treiberg

IPC: C07D403/12 ,  C07D491/107 ,  C07D409/14 ,  C07D413/14 ,  C07D401/14 ,  C07D403/14

CPC classification number: C07D403/12 ,  C07D401/14 ,  C07D403/14 ,  C07D409/14 ,  C07D413/14 ,  C07D491/107

Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.